BCM
TGTX icon

Bluefin Capital Management’s TG Therapeutics TGTX Stock Holding History

Bluefin Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-23,340
Closed -$230K – 471
2020
Q1 		$230K Buy
+23,340
New +$295K 0.03% 241

Other funds holding TGTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Bluefin Capital Management's TGTX Position: Q2 2020 in Review

Bluefin Capital Management sold out of TG Therapeutics (TGTX) in Q2 2020, closing a stake of 23,340 shares — an estimated $230K sold.

Bluefin Capital Management first reported a position in TGTX in Q1 2020 and held it in 1 quarter. The position peaked at $230K in Q1 2020. 175 funds tracked by Wall St. Rank hold TGTX as of Q2 2020.

  • Bluefin Capital Management reported no remaining TG Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Bluefin Capital Management sold 23,340 TG Therapeutics shares in Q2 2020, an estimated $230K.
  • Bluefin Capital Management first reported a position in TG Therapeutics in Q1 2020 and held it in 1 quarter.
  • Bluefin Capital Management's TG Therapeutics position peaked at $230K in Q1 2020.
  • 175 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2020.

Based on Bluefin Capital Management's 13F filing for Q2 2020, filed 17 Aug 2020.